secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261697
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics appoints Matthew Gall as CFO effective November 3, 2025
----------------------------------------------------------------------------

- Matthew Gall appointed CFO and Treasurer effective Nov 3, 2025; succeeds Brett Hagan as principal financial officer.
- Annual base salary of $485,000; eligible for target bonus of up to 40% of base salary.
- Received incentive stock option for 235,000 shares vesting over 4 years at closing price on grant date.
- Severance: 9 months salary (12 months if within 12 months of change in control) plus COBRA and accelerated equity.
- Gall previously CFO of iTeos Therapeutics (June 2020 – Aug 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525261697/0001193125-25-261697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525261697/d14509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer